
EyeGate Pharmaceuticals, Inc. Net Income | EYEG
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income EyeGate Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -8.09 M | -7.1 M | -10.8 M | -13.2 M | -13.3 M | -8.39 M | -1.77 M | -3.88 M | -6.03 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.77 M | -13.3 M | -8.07 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Clearside Biomedical
CLSD
|
-34.4 M | - | - | $ 25.3 M | ||
|
MEI Pharma
MEIP
|
-71.2 M | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
-8.38 M | - | - | $ 13 M | ||
|
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
-28.9 M | - | - | $ 24.9 M | ||
|
Завод ДИОД
DIOD
|
37.2 M | - | - | - | ||
|
Фармсинтез
LIFE
|
-525 M | - | - | - | ||
|
Ionis Pharmaceuticals
IONS
|
-381 M | $ 43.5 | 0.62 % | $ 6.96 B | ||
|
Agios Pharmaceuticals
AGIO
|
-413 M | $ 31.25 | 0.88 % | $ 1.81 B | ||
|
Foghorn Therapeutics
FHTX
|
-74.3 M | $ 2.0 | 0.74 % | $ 126 M | ||
|
Inhibikase Therapeutics
IKT
|
-48.3 M | $ 2.0 | 0.5 % | $ 197 M | ||
|
Kamada Ltd.
KMDA
|
20.2 M | $ 8.0 | 1.34 % | $ 461 M | ||
|
Intellia Therapeutics
NTLA
|
-413 M | $ 12.75 | 4.0 % | $ 1.38 B | ||
|
Ultragenyx Pharmaceutical
RARE
|
-575 M | $ 14.5 | 3.19 % | $ 1.43 B | ||
|
Viridian Therapeutics
VRDN
|
-343 M | $ 19.0 | 2.16 % | $ 1.93 B | ||
|
AbbVie
ABBV
|
1.82 B | $ 265.76 | 1.12 % | $ 470 B | ||
|
AbCellera Biologics
ABCL
|
-146 M | $ 13.78 | 0.29 % | $ 4.12 B | ||
|
Abeona Therapeutics
ABEO
|
-71.2 M | $ 5.11 | 1.59 % | $ 271 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-33.5 M | $ 4.67 | 4.94 % | $ 895 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
391 M | $ 20.11 | 0.8 % | $ 3.39 B | ||
|
Achieve Life Sciences
ACHV
|
-54.6 M | $ 7.01 | 0.13 % | $ 306 M | ||
|
AC Immune SA
ACIU
|
-70.4 M | $ 2.71 | 0.55 % | $ 273 M | ||
|
Aclaris Therapeutics
ACRS
|
-64.9 M | $ 4.27 | 0.79 % | $ 523 M | ||
|
Adagene
ADAG
|
-17.6 M | $ 2.8 | 0.28 % | $ 165 M | ||
|
ADC Therapeutics SA
ADCT
|
-143 M | $ 1.23 | 8.85 % | $ 156 M | ||
|
Adial Pharmaceuticals
ADIL
|
-7.98 M | $ 4.35 | 5.58 % | $ 2.91 M | ||
|
ADMA Biologics
ADMA
|
147 M | $ 10.11 | 4.01 % | $ 2.41 B | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
-59.5 M | $ 29.84 | 5.26 % | $ 4.53 B | ||
|
Agenus
AGEN
|
-3.08 M | $ 8.73 | 4.43 % | $ 260 M | ||
|
AIM ImmunoTech
AIM
|
-14 M | $ 0.19 | 5.56 % | $ 308 K | ||
|
Akebia Therapeutics
AKBA
|
-5.3 M | $ 0.91 | 5.26 % | $ 234 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 8.76 | 0.46 % | $ 590 B | ||
|
Aldeyra Therapeutics
ALDX
|
-33.8 M | $ 0.92 | 4.88 % | $ 55.3 M | ||
|
Alector
ALEC
|
-143 M | $ 1.99 | 9.94 % | $ 205 M | ||
|
Aligos Therapeutics
ALGS
|
-24.2 M | $ 5.4 | 0.36 % | $ 53.4 M | ||
|
Alkermes plc
ALKS
|
242 M | $ 42.76 | 2.42 % | $ 7.04 B | ||
|
Allogene Therapeutics
ALLO
|
-191 M | $ 1.5 | 0.33 % | $ 331 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
314 M | $ 219.89 | 0.08 % | $ 28.8 B | ||
|
Altimmune
ALT
|
-88.1 M | $ 2.67 | 0.36 % | $ 235 M | ||
|
ALX Oncology Holdings
ALXO
|
-102 M | $ 1.21 | 1.23 % | $ 64.9 M | ||
|
Amgen
AMGN
|
7.71 B | $ 402.98 | 0.08 % | $ 217 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
98.1 M | $ 25.37 | 0.39 % | $ 1.19 B | ||
|
Amarin Corporation plc
AMRN
|
-38.8 M | $ 12.09 | 0.31 % | $ 5.02 B | ||
|
Amneal Pharmaceuticals
AMRX
|
72.1 M | $ 20.35 | 0.25 % | $ 6.38 B | ||
|
AnaptysBio
ANAB
|
131 M | $ 49.2 | 1.38 % | $ 1.43 B | ||
|
Anika Therapeutics
ANIK
|
-10.9 M | $ 19.73 | 3.3 % | $ 283 M | ||
|
ANI Pharmaceuticals
ANIP
|
78 M | $ 72.58 | 0.55 % | $ 1.46 B |